Xeris Biopharma Holdings, Inc./$XERS
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Xeris Biopharma Holdings, Inc.
Xeris Biopharma Holdings Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for people with chronic endocrine and neurological diseases in the United States. It offers Recorlev for the treatment of endogenous hypercortisolemia in patients with Cushing's syndrome; Gvoke for the treatment of severe hypoglycemia; and Keveyis for the treatment of Primary Periodic Paralysis (PPP). Additionally, the company is advancing its Phase 3-ready pipeline product, XP-8121, a once-weekly subcutaneous injection of levothyroxine, which leverages its proprietary technology, XeriSol.
Ticker
$XERS
Sector
Primary listing
Employees
435
Headquarters
Website
XERS Metrics
BasicAdvanced
$1.2bn
107.33
$0.06
0.92
-
Price and volume
Market cap
$1.2bn
Beta
0.92
52-week high
$10.08
52-week low
$4.36
Average daily volume
1.8m
Financial strength
Current ratio
2.122
Quick ratio
1.417
Long term debt to equity
1,938.99
Total debt to equity
1,987.188
Interest coverage (TTM)
1.25%
Profitability
EBITDA (TTM)
48.08
Gross margin (TTM)
85.89%
Net profit margin (TTM)
3.81%
Operating margin (TTM)
11.40%
Revenue per employee (TTM)
$720,000
Management effectiveness
Return on assets (TTM)
6.34%
Return on equity (TTM)
-108.59%
Valuation
Price to earnings (TTM)
107.327
Price to revenue (TTM)
3.604
Price to book
91.25
Price to tangible book (TTM)
-12.47
Price to free cash flow (TTM)
23.881
Free cash flow yield (TTM)
4.19%
Free cash flow per share (TTM)
0.288
Growth
Revenue change (TTM)
41.47%
Earnings per share change (TTM)
-121.30%
3-year revenue growth (CAGR)
37.40%
3-year earnings per share growth (CAGR)
-51.77%
XERS News
AllArticlesVideos
Xeris Biopharma Announces Notice of Allowance From U.S. Patent and Trademark Office for New Patent Covering KEVEYIS®
Business Wire·5 days ago
Xeris Biopharma Q1 Earnings Call Highlights
MarketBeat·1 month ago
Xeris Biopharma to Report First Quarter 2026 Financial Results on May 7, 2026
Business Wire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs